Head and Neck Diseases by Alexandros G.Sfakianakis: Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Τρίτη 13 Νοεμβρίου 2018

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Conditions: Stage II-IVB Operable HNSCC Oral Cavity; Hypopharynx; Oropharynx; Larynx
Interventions: Drug: Durvalumab; Drug: durvalumab + tremelimumab
Sponsor: Yonsei University
Not yet recruiting

https://ift.tt/2qL8jn4

Head and Neck Diseases by Alexandros G.Sfakianakis

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τρίτη 13 Νοεμβρίου 2018

Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου